Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

1.

Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases.

Mai KT, Commons AS, Perkins DG, Yazdi HM, Collins JP.

Hum Pathol. 1996 Dec;27(12):1377-81.

PMID:
8958315
[PubMed - indexed for MEDLINE]
2.

A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.

Tarle M, Frković-Grazio S, Kraljić I, Kovacić K.

Prostate. 1994;24(3):143-8.

PMID:
7509485
[PubMed - indexed for MEDLINE]
3.

Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.

Grob BM, Schellhammer PF, Brassil DN, Wright GL Jr.

Urology. 1994 Oct;44(4):525-9.

PMID:
7524238
[PubMed - indexed for MEDLINE]
4.

Prostate-specific antigen as a marker of adenocarcinoma of prostate.

Kellokumpu-Lehtinen P, Nurmi M, Koskinen P, Irjala K.

Urol Res. 1989;17(4):245-9.

PMID:
2475959
[PubMed - indexed for MEDLINE]
5.

Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.

Soga N, Onishi T, Arima K, Sugimura Y.

Int J Urol. 2007 Mar;14(3):192-6; discussion 197.

PMID:
17430253
[PubMed - indexed for MEDLINE]
6.

The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.

Ersev A, Ersev D, Turkeri L, Ilker Y, Simsek F, Kullu S, Akdas A.

Prog Clin Biol Res. 1990;357:129-34.

PMID:
1699237
[PubMed - indexed for MEDLINE]
7.

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.

Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL.

Cancer. 2007 Jan 15;109(2):198-204.

PMID:
17171704
[PubMed - indexed for MEDLINE]
Free Article
8.

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG.

Urology. 1997 Jun;49(6):857-62.

PMID:
9187691
[PubMed - indexed for MEDLINE]
9.

Prostate-specific antigen in the follow-up of prostatic adenocarcinoma treated with external beam radiation.

Kellokumpu-Lehtinen P, Nurmi M, Koskinen P, Irjala K.

Urol Int. 1991;46(1):6-8.

PMID:
1708923
[PubMed - indexed for MEDLINE]
10.

DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.

Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fosså SD.

Br J Urol. 1995 Jan;75(1):26-32.

PMID:
7531589
[PubMed - indexed for MEDLINE]
11.

High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.

Tavora F, Epstein JI.

Am J Surg Pathol. 2008 Jul;32(7):1060-7. doi: 10.1097/PAS.0b013e318160edaf.

PMID:
18496142
[PubMed - indexed for MEDLINE]
12.

[Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].

Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K.

Hinyokika Kiyo. 2007 Jul;53(7):489-92. Japanese.

PMID:
17702184
[PubMed - indexed for MEDLINE]
Free Article
13.

The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.

Sheridan T, Herawi M, Epstein JI, Illei PB.

Am J Surg Pathol. 2007 Sep;31(9):1351-5.

PMID:
17721190
[PubMed - indexed for MEDLINE]
14.

Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.

Lilleby W, Paus E, Skovlund E, Fosså SD.

Prostate. 2001 Feb 1;46(2):126-33.

PMID:
11170140
[PubMed - indexed for MEDLINE]
15.

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP.

Cancer. 1998 Jun 1;82(11):2256-61.

PMID:
9610707
[PubMed - indexed for MEDLINE]
16.

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.

Wang W, Epstein JI.

Am J Surg Pathol. 2008 Jan;32(1):65-71.

PMID:
18162772
[PubMed - indexed for MEDLINE]
17.

Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.

Nishiyama T, Terunuma M.

Int J Urol. 1994 Dec;1(4):355-6.

PMID:
7542158
[PubMed - indexed for MEDLINE]
18.

Morphological features correlation with serum tumour markers in prostatic carcinoma.

Afzal S, Ahmad M, Mushtaq S, Mubarik A, Qureshi AH, Khan SA.

J Coll Physicians Surg Pak. 2003 Sep;13(9):511-4.

PMID:
12971871
[PubMed - indexed for MEDLINE]
19.

Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy.

Grignon D, Troster M.

Prostate. 1985;7(2):195-202.

PMID:
2413432
[PubMed - indexed for MEDLINE]
20.

Adenocarcinoma of the prostate involving 2 cell types (prostate specific antigen producing and carcinoembryonic antigen producing) with selective metastatic spread.

Guthman DA, Farrow GM, Myers RP, Ferrigni RG, Lieber MM.

J Urol. 1991 Sep;146(3):854-6.

PMID:
1714970
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk